Estrogen and androgen hormone therapy and well-being in surgically postmenopausal women

Journal of Women's Health

Volumn 15, Issue 8, 2006, Pages 898-908

  Kotz, Krista ^a   Alexander, Jeanne Leventhal ^b,c,d   Dennerstein, Lorraine ^e  

^a Kotz Health Policy Consulting   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Alexander Foundation for Women's Health   (United States)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CONJUGATED ESTROGEN; ESTRADIOL VALERATE; ESTROGEN; PLACEBO; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ACNE; BODY WEIGHT DISORDER; CLINICAL TRIAL; COCHRANE LIBRARY; DOSE RESPONSE; ESTROGEN BLOOD LEVEL; EVIDENCE BASED MEDICINE; FEMALE; HAIR GROWTH; HEMATOLOGIC DISEASE; HIRSUTISM; HORMONE DETERMINATION; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; LIVER DISEASE; MEDICAL DECISION MAKING; MEDLINE; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SELF ESTEEM; SEXUAL FUNCTION; SEXUAL SATISFACTION; SIDE EFFECT; SOCIAL LIFE; SOCIAL WORK; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL; THERAPY EFFECT; TRANSDERMAL PATCH; WEIGHT GAIN; WELLBEING; WOMEN'S HEALTH;

AFFECT; ANDROGENS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; HYSTERECTOMY; LIBIDO; MENOPAUSE; QUALITY OF LIFE; TESTOSTERONE; WOMEN'S HEALTH;

EID: 33751247645     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2006.15.898     Document Type: Review

References (57)

1. Alder E. How to assess quality of life problems and methodology. In: Schneider H, ed. Hormone Replacement Therapy and Quality of Life. Boca Raton, FL: The Parthenon Publishing Group, 2002.
2. WHO-QOL Study Protocol. The development of the World Health Organization quality of life assessment instrument. Geneva, Switzerland: World Health Organization, 1993.
3. Schneider H, Behre H. Contemporary evaluation of climacteric complaints: Its impact on quality of life. In: Schneider H, ed. Hormone replacement therapy and quality of life. Boca Raton: The Parthenon Publishing Group, 2002.
4. Dudley EC, Hopper JL, Taffe J, Guthrie JR, Burger HG, Dennerstein L. Using longitudinal data to define the perimenopause by menstrual cycle characteristics. Climacteric 1998;1:18.
5. Dennerstein L, Dudley E, Hopper J, Guthrie J, Burger H. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351.
6. Farquhar C, Sadler L, Harvey S, McDougall J, Yazdi G, Meuli K. A prospective study of the short-term outcomes of hysterectomy with and without oophorectomy. Aust NZ J Obstet Gynaecol 2002;42:197.
7. Avis NE, Crawford S, Stellato R, Longcope C. Longitudinal study of hormone levels and depression among women transitioning through menopause. Climacteric 2001;4:243.
8. Dennerstein L, Burrows GD, Hyman GJ, Sharpe K. Hormone therapy and affect. Maturitas 1979;1:247.
9. Dennerstein L, Lehert P, Burger H, Dudley E. Mood and the menopausal transition. J Nerv Ment Dis 1999;187:685.
10. Kronenberg F. Hot flashes: Epidemiology and physiology. Ann NY Acad Sci 1990;592:52.
11. Reynolds F. Some relationships between perceived control and women's reported coping strategies for menopausal hot flushes. Maturitas 1999;32:25.
12. Woodward S, Freedman R. The thermoregulatory effects of menopausal hot flashes on sleep. Sleep 1994;17:497.
13. ACOG. Issues in women's health. Washington, DC: Office of Public Information, 1992.
14. Sarrel P. Sexuality in the middle years. Obstet Gynecol Clin North Am 1987;14:49.
15. Chakravarti S, Collins WP, Newton JR, Oram DH, Studd JW. Endocrine changes and symptomatology after oophorectomy in premenopausal women. Br J Obstet Gynaecol 1977;84:769.
16. Dennerstein L, Wood C, Burrows G. Sexual response following hysterectomy and oophorecomy. Obstet Gynecol 1977;49:92.
17. Saini J, Kuczynski E, Gretz Hr, Sills E. Supracervical hysterectomy versus total abdominal hysterectomy: Perceived effects on sexual function. BMC Womens Health 2002;2:1.
18. Rubinow D, Schmidt P. Androgens, brain, and behavior. Am J Psychiatry 1996;153:974.
19. Rubinow D, Schmidt P, Roca C. Estrogen-serotonin interactions: Implications for affective regulation. Biol Psychiatry 1998;44:839.
20. Laughlin G, Barrett-Connor E, Kritz-Silverstein D, von Muhlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: The Rancho Bernardo Study. J Clin Endocrinol Metab 2000;85:645.
21. Davison S, Bell R, Donath S, Montalto J, Davis S. Androgen levels in adult females: Changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90:3847.
22. Davis S, Goldstat R, Papalia M, et al. Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: A randomised placebo-controlled trial. Menopause 2006;13:37.
23. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227.
24. Burger H, Hailes J, Nelson J, Menelaus M. Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women. Br Med J(Clin Res Ed) 1987;294:936.
25. Nathorst-Boos J, Floter A, Jarkander-Rolff M, Carlstrom K, Schoultz B. Treatment with percutanous testosterone gel in postmenopausal women with decreased libido - Effects on sexuality and psychological general well-being. Maturitas 2006;53:11.
26. Lobo R, Rosen R, Yang H, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003;79:1341.
27. Myers L, Dixen J, Morrissette D, Carmichael M, Davidson J. Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women. J Clin Endocrinol Metab 1990;70:1124.
28. Dobs A, Nguyen T, Pace C, Roberts C. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. J Clin Endocrinol Metab 2002;87:1509.
29. Braunstein G, Sundwall D, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Arch Intern Med 2005;165:1582.
30. Buster J, Kingsberg S, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: A randomized trial. Obstet Gynecol 2005;105:944.
31. Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90:5226.
32. Warnock J, Swanson S, Borel R, Zipfel L, Brennan JJ, Group ECS. Combined esterified estrogens and methyltestosterone versus esterified estrogens alone in the treatment of loss of sexual interest in surgically menopausal women. Menopause 2005;12:374.
33. Floter A, Nathorst-Boos J, Carlstrom K, von Schoultz B. Addition of testosterone to estrogen replacement therapy in oophorectomized women: Effects on sexuality and well-being. Climacteric 2002;5:357.
34. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682.
35. Sherwin B, Gelfand M. Sex steroids and affect in the surgical menopause: A double-blind, cross-over study. Psychoneuroendocrinology 1985;10:325.
36. Alexander J, Dennerstein L, Burger H, Graziottin A. Testosterone and libido in surgically and naturally postmenopause woman. Women's Health 2006;2:459.
37. Dupuy H. The Psychological General Well-being (PGWB) index. In: Wenger N MM, Furberg C, Elinson J, ed. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: Le Jacq Publishing, 1984:170.
38. Wiklund I, Karlberg J. Evaluation of quality of life in clinical trials. Selecting quality-of-life measures. Control Clin Trials 1991;12:204S.
39. Nathorst-Boos J, von Schoultz B, Carlstrom K. Elective ovarian removal and estrogen replacement therapy - Effects on sexual life, psychological well-being and androgen status. J Psychosom Obstet Gynaecol 1993;14:283.
40. Wiklund I, Berg G, Hammar M, Karlberg J, Lindgren R, Sandin K. Long-term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women. Maturitas 1992;14:225.
41. McCoy N, Davidson J. A longitudinal study of the effects of menopause on sexuality. Maturitas 1985;7: 203.
42. Sherwin B. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab 1991; 72:336.
43. Dennerstein L, Burrows GD, Wood C, Hyman G. Hormones and sexuality: Effect of estrogen and progestogen. Obstet Gynecol 1980;56:316.
44. Haines CJ, Yim SF, Chung TK, et al. A prospective, randomized, placebo-controlled study of the dose effect of oral estradiol on menopausal symptoms, psychological well-being, and quality of life in postmenopausal Chinese women. Maturitas 2003; 44:207.
45. The World Health Organization Quality of Life Assessment (WHOQOL): Development and general psychometric properties. Soc Sci Med 1998;46:1569.
46. Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual Life Res 1993;2:153.
47. Leung K, Chu M, Lau J. Cultural relevancy of WHOQOL structure in Hong Kong Chinese. Quality of Life Symposium. Hong Kong, 1997.
48. Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000;152:463.
49. Alexander J, Kotz K, Dennerstein L, Kutner S, Wallen K, Notelovitz M. The effects of postmenopausal hormone therapies on female sexual functioning: A review of double-blind, randomized controlled trials. Menopause 2004;11:749.
50. Baracat E, Haidar M, Lopez FJ, Pickar J, Dey M, Negro-Vilar A. Estrogen activity and novel tissue selectivity of delta 8,9-dehydroestrone sulfate in postmenopausal women. J Clin Endocrinol Metab 1999;84:2020.
51. Speroff L, Whitcomb RW, Kempfert NJ, Boyd RA, Paulissen JB, Rowan JP. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstet Gynecol 1996;88:587.
52. Callantine MR, Martin PL, Bolding OT, Warner PO, Greaney MO Jr. Micronized 17 beta-estradiol for oral estrogen therapy in menopausal women. Obstet Gynecol 1975;46:37.
53. Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17 beta-estradiol. Menopause 2000;7:310.
54. Steingold KA, Laufer L, Chetkowski RJ, et al. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab 1985;61:627.
55. Utian WH, Janata JW, Kingsberg SA, Schluchter M, Hamilton JC. The Utian Quality of Life (UQQL) scale: Development and validation of an instrument to quantify quality of life through and beyond menopause. Menopause 2002;9:402.
56. Utian WH, Janata JW, Barbier S, Rosen AS, Mayer MH, Taylor MB. Effect of raloxifene on quality of life: A prospective study using the Utian Quality of Life (UQOL) scale. Menopause 2004;11:275.
57. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321.